CZ302615B6 - Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid - Google Patents
Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid Download PDFInfo
- Publication number
- CZ302615B6 CZ302615B6 CZ20002373A CZ20002373A CZ302615B6 CZ 302615 B6 CZ302615 B6 CZ 302615B6 CZ 20002373 A CZ20002373 A CZ 20002373A CZ 20002373 A CZ20002373 A CZ 20002373A CZ 302615 B6 CZ302615 B6 CZ 302615B6
- Authority
- CZ
- Czechia
- Prior art keywords
- capsular polysaccharide
- polysaccharide
- capsular
- cps
- gram
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 160
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 158
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 78
- 230000001413 cellular effect Effects 0.000 title claims abstract description 27
- 241000192125 Firmicutes Species 0.000 title claims abstract description 13
- 230000001580 bacterial effect Effects 0.000 claims abstract description 39
- 239000006228 supernatant Substances 0.000 claims abstract description 24
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 239000012535 impurity Substances 0.000 claims abstract description 16
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 15
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000003636 conditioned culture medium Substances 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 56
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 239000003795 chemical substances by application Substances 0.000 claims description 32
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 30
- 229960005486 vaccine Drugs 0.000 claims description 30
- 238000000605 extraction Methods 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 23
- 239000002775 capsule Substances 0.000 claims description 21
- 238000005227 gel permeation chromatography Methods 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 238000004587 chromatography analysis Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims description 11
- 241000194017 Streptococcus Species 0.000 claims description 10
- 125000003172 aldehyde group Chemical group 0.000 claims description 10
- 241000588650 Neisseria meningitidis Species 0.000 claims description 9
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 8
- 125000003277 amino group Chemical group 0.000 claims description 8
- 238000013375 chromatographic separation Methods 0.000 claims description 8
- 108010060123 Conjugate Vaccines Proteins 0.000 claims description 6
- 229920002684 Sepharose Polymers 0.000 claims description 6
- 229940031670 conjugate vaccine Drugs 0.000 claims description 6
- 230000001268 conjugating effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 claims description 5
- SMWZGZIZOHNWBH-UHFFFAOYSA-N 3-bromo-5-phenyl-1,2-oxazole Chemical compound O1N=C(Br)C=C1C1=CC=CC=C1 SMWZGZIZOHNWBH-UHFFFAOYSA-N 0.000 claims description 5
- 230000021615 conjugation Effects 0.000 claims description 5
- 150000002009 diols Chemical group 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 238000006268 reductive amination reaction Methods 0.000 claims description 5
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012346 acetyl chloride Substances 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 150000007530 organic bases Chemical class 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 210000003850 cellular structure Anatomy 0.000 claims description 2
- 238000011210 chromatographic step Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 229920001231 Polysaccharide peptide Polymers 0.000 claims 1
- 230000001143 conditioned effect Effects 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 108010022457 polysaccharide peptide Proteins 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 8
- 108010013639 Peptidoglycan Proteins 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- -1 Acetal hydride Chemical class 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000012465 retentate Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000000569 multi-angle light scattering Methods 0.000 description 5
- 150000004713 phosphodiesters Chemical class 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 125000003047 N-acetyl group Chemical group 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000617590 Escherichia coli K1 Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 108090000988 Lysostaphin Proteins 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 239000012345 acetylating agent Substances 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000011097 chromatography purification Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000002013 hydrophilic interaction chromatography Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108010009719 mutanolysin Proteins 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 235000020030 perry Nutrition 0.000 description 3
- 238000005375 photometry Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- GHAXTSRJNHYMFC-SANMLTNESA-N (2s)-3-(4-hydroxyphenyl)-2-(octadecylamino)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCCN[C@H](C(O)=O)CC1=CC=C(O)C=C1 GHAXTSRJNHYMFC-SANMLTNESA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000186811 Erysipelothrix Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000282838 Lama Species 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 2
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 206010061372 Streptococcal infection Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000007248 oxidative elimination reaction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 108020004513 Bacterial RNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010594 Congenital pneumonia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010061190 Haemophilus infection Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 230000006181 N-acylation Effects 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010042178 Streptococcal impetigo Diseases 0.000 description 1
- 206010048960 Streptococcal sepsis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010044013 Tonsillitis streptococcal Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- OGEROIBRQCWGOI-UHFFFAOYSA-N hexanedioic acid;hydrazine Chemical compound NN.NN.OC(=O)CCCCC(O)=O OGEROIBRQCWGOI-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229940060155 neuac Drugs 0.000 description 1
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Inorganic materials [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6860897P | 1997-12-23 | 1997-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CZ20002373A3 CZ20002373A3 (cs) | 2000-12-13 |
| CZ302615B6 true CZ302615B6 (cs) | 2011-08-03 |
Family
ID=22083630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20002373A CZ302615B6 (cs) | 1997-12-23 | 1998-12-23 | Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6248570B1 (enExample) |
| EP (3) | EP1051506B2 (enExample) |
| JP (2) | JP4435413B2 (enExample) |
| KR (2) | KR100757630B1 (enExample) |
| AT (1) | ATE468403T2 (enExample) |
| AU (1) | AU754256C (enExample) |
| CA (1) | CA2316975C (enExample) |
| CZ (1) | CZ302615B6 (enExample) |
| DE (1) | DE69841676D1 (enExample) |
| DK (1) | DK1051506T4 (enExample) |
| ES (2) | ES2346022T3 (enExample) |
| HU (1) | HUP0100623A3 (enExample) |
| NO (1) | NO331100B1 (enExample) |
| WO (1) | WO1999032653A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU66103A (sh) | 2001-01-23 | 2006-05-25 | Aventis Pasteur | Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina |
| US8222232B2 (en) * | 2001-02-16 | 2012-07-17 | Cargill, Incorporated | Glucosamine and N-acetylglucosamine compositions and methods of making the same fungal biomass |
| US7816514B2 (en) | 2001-02-16 | 2010-10-19 | Cargill, Incorporated | Glucosamine and method of making glucosamine from microbial biomass |
| US6693188B2 (en) | 2001-08-08 | 2004-02-17 | Cargill Incorporated | N-acetyl-D-glucosamine and process for producing N-acetyl-D-glucosamine |
| US7923437B2 (en) * | 2001-02-16 | 2011-04-12 | Cargill, Incorporated | Water soluble β-glucan, glucosamine, and N-acetylglucosamine compositions and methods for making the same |
| US20020115639A1 (en) * | 2001-02-16 | 2002-08-22 | Weiyu Fan | Glucosamine and method of making glucosamine from microbial blomass |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| ATE419278T1 (de) * | 2002-03-26 | 2009-01-15 | Novartis Vaccines & Diagnostic | Modifizierte saccharide mit verbesserter stabilität in wasser |
| US20040096461A1 (en) * | 2002-07-30 | 2004-05-20 | Baxter Healthcare Corporation | Chimeric multivalent polysaccharide conjugate vaccines |
| US20060058263A1 (en) * | 2002-11-01 | 2006-03-16 | Rogers Brent D | Heat pasturized liquids containing glucosamine |
| US20060003965A1 (en) * | 2002-11-01 | 2006-01-05 | Fosdick Lawrence D | N-acetyl-d-glucosamine (nag) supplemented food products and beverages |
| CN102319427A (zh) | 2003-01-30 | 2012-01-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
| US20070020293A1 (en) * | 2003-06-23 | 2007-01-25 | Michon Francis J | Vaccines against group neisseria meningitidis and meningococcal combinations thereof |
| GB0406013D0 (en) * | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| WO2006016161A1 (en) * | 2004-08-12 | 2006-02-16 | Lipoxen Technologies Limited | Fractionation of charged polysaccharide |
| GB0502096D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
| GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| CN104815327A (zh) | 2005-04-08 | 2015-08-05 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
| AU2011253684B8 (en) * | 2005-04-08 | 2013-07-11 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA2620416A1 (en) * | 2005-08-24 | 2007-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Zwitterionization of capsular saccharides |
| GB0522303D0 (en) | 2005-11-01 | 2005-12-07 | Chiron Srl | Culture method |
| JP5286089B2 (ja) * | 2006-01-13 | 2013-09-11 | バクスター・インターナショナル・インコーポレイテッド | ポリサッカライドを精製する方法 |
| US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| GB0605757D0 (en) * | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| US10543265B2 (en) | 2006-03-22 | 2020-01-28 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| EP1872791A1 (en) | 2006-06-30 | 2008-01-02 | Institut Pasteur | Use of bacterial polysaccharides for biofilm inhibition |
| PL2115010T3 (pl) | 2007-02-28 | 2012-07-31 | Lipoxen Tech Limited | Zmniejszanie zawartości endotoksyny w kwasach polisialowych |
| HUE038598T2 (hu) | 2007-03-05 | 2018-10-29 | Om Pharma | Bakteriális extraktum légzési rendellenességekhez, és eljárás ennek elõállítására |
| DK2436700T5 (en) * | 2007-03-23 | 2018-09-03 | Wyeth Llc | BRIEF PURIFICATION PROCEDURE FOR THE PREPARATION OF STREPTOCOCCUS PNEUMONIAE-Capsule POLYACCHARIDES |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| JP5339243B2 (ja) * | 2008-04-24 | 2013-11-13 | 株式会社微生物化学研究所 | ストレプトコッカス・スイス感染症予防用ワクチン |
| WO2011005587A1 (en) * | 2009-06-24 | 2011-01-13 | University Of Dubuque | Vaccine compositions and methods of use to protect against infectious disease |
| JP5944480B2 (ja) * | 2011-03-22 | 2016-07-05 | セルム・インスティテュート・オブ・インディア・ピーブイティー．・リミテッド | 多糖を調製するための新規な方法 |
| US9400250B2 (en) | 2013-09-30 | 2016-07-26 | Han Sheng Biotech Co., Ltd. | Method for analyzing mushrooms |
| MY186874A (en) * | 2014-02-25 | 2021-08-26 | Msd Wellcome Trust Hilleman Laboratories Pvt Ltd | A novel downstream process for purifying polysaccharides |
| EP2942396A1 (en) | 2014-05-07 | 2015-11-11 | Novartis AG | Polysaccharides produced by CPSC mutants |
| EP3034516A1 (en) * | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide |
| KR102045663B1 (ko) | 2015-05-04 | 2019-11-15 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| WO2018104889A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Biologicals Sa | Purification process for capsular polysaccharide |
| KR102565771B1 (ko) * | 2017-05-05 | 2023-08-10 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | 박테리아 협막 폴리사카라이드 기반 제제로부터의 불순물의 제거 방법 |
| JP7111799B2 (ja) * | 2017-07-05 | 2022-08-02 | インベントプライズ リミテッド ライアビリティ カンパニー | 溶菌酵素、接線流濾過、及びマルチモードクロマトグラフィを用いたワクチン生産のための多糖精製 |
| SI3678654T1 (sl) | 2017-09-07 | 2024-10-30 | Merck Sharp & Dohme Llc | Pnevmokokni polisaharidi in njihova uporaba v imunogenih polisaharidnih nosilnih proteinskih konjugatih |
| FR3078977B1 (fr) | 2018-03-16 | 2023-03-17 | Biomerieux Sa | Procede d'extraction d'acides nucleiques |
| EP4232593A1 (en) * | 2020-10-22 | 2023-08-30 | Pfizer Inc. | Methods for purifying bacterial polysaccharides |
| CN117512031B (zh) * | 2023-10-16 | 2024-06-25 | 江苏金迪克生物技术股份有限公司 | 一种肺炎球菌荚膜多糖的纯化方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4413057A (en) * | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
| EP0238739A1 (en) * | 1986-03-27 | 1987-09-30 | Swiss Serum and Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3523801A (en) | 1966-01-13 | 1970-08-11 | Kyowa Hakko Kogyo Kk | Process for the preparation of seasonings |
| US3577527A (en) * | 1969-01-27 | 1971-05-04 | Us Navy | Neisseria meningitidis antigen |
| US4258029A (en) | 1979-04-23 | 1981-03-24 | Connaught Laboratories Limited | Synthetic adjuvants for stimulation of antigenic responses |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4644059A (en) * | 1982-07-06 | 1987-02-17 | Connaught Laboratories, Inc. | Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine |
| AU586857B2 (en) * | 1986-03-27 | 1989-07-27 | Swiss Serum And Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5190746A (en) | 1989-05-10 | 1993-03-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Plaque inhibiting oligosaccharide |
| DK0504202T3 (da) | 1989-12-14 | 1995-10-02 | Ca Nat Research Council | Forbedret meningokok-polysaccharid-konjugat vaccine |
| NZ239643A (en) | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
| ZA937034B (en) * | 1992-09-24 | 1995-06-23 | Brigham & Womens Hospital | Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines |
| US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
-
1998
- 1998-12-23 CZ CZ20002373A patent/CZ302615B6/cs not_active IP Right Cessation
- 1998-12-23 EP EP98966468.5A patent/EP1051506B2/en not_active Expired - Lifetime
- 1998-12-23 WO PCT/US1998/027375 patent/WO1999032653A1/en not_active Ceased
- 1998-12-23 KR KR1020067013976A patent/KR100757630B1/ko not_active Expired - Fee Related
- 1998-12-23 CA CA002316975A patent/CA2316975C/en not_active Expired - Lifetime
- 1998-12-23 HU HU0100623A patent/HUP0100623A3/hu unknown
- 1998-12-23 ES ES98966468T patent/ES2346022T3/es not_active Expired - Lifetime
- 1998-12-23 EP EP10005184.6A patent/EP2226336B1/en not_active Expired - Lifetime
- 1998-12-23 JP JP2000525570A patent/JP4435413B2/ja not_active Expired - Lifetime
- 1998-12-23 KR KR1020007006995A patent/KR100641490B1/ko not_active Expired - Lifetime
- 1998-12-23 US US09/221,630 patent/US6248570B1/en not_active Expired - Lifetime
- 1998-12-23 DK DK98966468.5T patent/DK1051506T4/da active
- 1998-12-23 ES ES10005184.6T patent/ES2611464T3/es not_active Expired - Lifetime
- 1998-12-23 AU AU23071/99A patent/AU754256C/en not_active Expired
- 1998-12-23 EP EP16182410.7A patent/EP3118225A1/en not_active Withdrawn
- 1998-12-23 AT AT98966468T patent/ATE468403T2/de active
- 1998-12-23 DE DE69841676T patent/DE69841676D1/de not_active Expired - Lifetime
-
2000
- 2000-06-21 NO NO20003226A patent/NO331100B1/no not_active IP Right Cessation
-
2009
- 2009-09-07 JP JP2009206304A patent/JP5144613B2/ja not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4413057A (en) * | 1980-04-14 | 1983-11-01 | Merck & Co., Inc. | Group B streptococcal capsular polysaccharides |
| EP0238739A1 (en) * | 1986-03-27 | 1987-09-30 | Swiss Serum and Vaccine Institute Berne | Klebsiella capsular polysaccharide vaccine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ302615B6 (cs) | Zpusob cištení kapsulárních polysacharidu od bunecných komponent gramnegativních a grampozitivních bakterií a modifikovaný kapsulární polysacharid | |
| JP5286089B2 (ja) | ポリサッカライドを精製する方法 | |
| Kogan et al. | Structural and immunochemical characterization of the type VIII group B Streptococcus capsular polysaccharide | |
| Fournier et al. | Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide | |
| CN109134677A (zh) | 金黄色葡萄球菌5型和8型荚膜多糖的纯化 | |
| EP0302887B1 (en) | Bacterial antigens, antibodies, vaccines, and methods of manufacture | |
| US20010051364A1 (en) | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines | |
| RU2818894C1 (ru) | Свободные от примеси с-полисахарида капсульные полисахариды streptococcus pneumoniae с остатком 2,5-ангидроманнозы на восстанавливающем конце | |
| HK1147506B (en) | Bacterial capsular polysaccharide for use as vaccines or for linking to proteins in conjugate vaccines | |
| CN115724940B (zh) | 靶向STAT3蛋白Tyr705磷酸化的肽及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD00 | Pending as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20181223 |